An Improved Therapeutic Approach
How It Works
The components of AXS-06, MoSEIC™ meloxicam and rizatriptan, are combined for a potentially synergistic effect with enhanced efficacy over currently available therapies in the treatment of migraine. Meloxicam is an NSAID that provides potent pain relief with a long duration of action. However, standard meloxicam has an extended time to maximum plasma concentration (Tmax). AXS-06 utilizes Axsome’s proprietary MoSEIC™ technology to achieve rapid peak plasma levels of meloxicam after oral administration without compromising its long half-life. Rizatriptan is currently approved as a single agent for the acute treatment of migraine and targets different migraine-inducing CNS receptor systems than meloxicam
Based on Pre-Investigational New Drug Application (Pre-IND) guidance from the U.S Food and Drug Administration (FDA), AXS-06 is planned for a Phase 3 trial.
Osteoarthritis and Rheumatoid Arthritis
Osteoporosis is a degenerative bone condition characterized by an imbalance in bone resorption and formation resulting in porous and brittle bones that are prone to fracture.